BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
BioMarin licensed worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting subcutaneous enzyme replacement therapy for Fabry disease, from GC Biopharma and Hanmi Pharm. BioMarin will pay $70 million upfront with up to $405 million more in development and commercial milestones plus tiered royalties; the candidate is in a Phase 1/2 trial and holds FDA Orphan Drug Designation.
Key figures
- Drug Name
- HM15421/GC1134A
- Phase Of Trial
- Phase 1/2
- Upfront payment
- 70000000
- Potential milestones
- 405000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.